Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

ADDvise Group, Audiocast with teleconference, Q3'24

By Inderes10/24/2024, 12:00 PM
ADDvise Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Staffan Torstensson
00:00 - 00:00

Go ahead.

Johan Irwe
00:03 - 12:53

Thank you. And once again, welcome to Addvise Group's Q3 2024 Earnings Call. We will take you through the business update and the group's financial performance, and then we will open up for a Q&A session. Q3 was a stable quarter. Our net sales came in at 404 million SEK, which takes us to a year-on-year growth of 26%. However, we continue to see challenging comparables in pharma and clinical trials following last year's stellar performance. This effect will remain, but on a lower level during Q4, with no effect from Q1 next year and onwards. That led us to isolated negative organic growth of -25% for the quarter. EBITA came in at 88 million SEK, which takes us to a 22% EBITDA margin. To provide more insight into the underlying business, if we exclude pharma and clinical trials, we observed an organic growth of 6% for the first nine months. We had a stable order intake in the quarter, up 17%. Year on year, the quarter saw one of the biggest orders in the Nordics ever, but otherwise no big outliers. EBITDA came in at 74 million SEK versus 71 million, a small increase of 4%, mainly due to normalized depreciation levels in clinical trials. Looking at the cash flow from operations, it was 32 million SEK, mainly affected by growth-related CapEx, investments in production capacity, and growth in our clinical trials business. Cash on hand is approximately 400 million SEK. On the M&A side, we cautiously monitor the net leverage and keep that in mind while looking at new opportunities. Coming into the commercial and operational highlights of Q3, we saw some improvements in business momentum, but from moderate levels during the quarter. Our recently acquired businesses are performing according to or slightly above plan, and the lion's share of them will start to affect organic growth in Q4. But we will still experience some effects from the exceptional performance of the pharma business during Q4 2024. In terms of geography, 45% of our sales in the quarter isolated came from North America, and our second largest market in Europe, excluding Sweden. And the third largest market is South America. Looking at our sales by product category. The top three product categories year to date are medical consumables, followed by lab equipment and then medical devices. As you can see on this pie chart, Pharma is now stabilizing around 7% of our sales year to date. And compare that to last year or the peak levels in pharma. Pharma was about 20 to 25% of sales. We clearly see signs of improvement in the demand for capital goods in the US during the quarter. Our sales have been growing over the last four years. As you can see now, we are about $1.5 billion in sales. And if you look at the quarter in isolation. We came in at 404 million SEK. SEK, an organic drop of 19% due to the elements I just mentioned. We also measure our revenues in own products. Products that we develop and manufacture, and products that we distribute. Q3 year to date, own products came in at 56% of our sales, and that is a level we are satisfied with going forward. Order intake. The quarter recorded a healthy growth of 17%. New orders received amounted to 442 million for the quarter. As I said earlier, there was no single big contributor. However, the Nordics were strong. Uh, and we see improving momentum in the US. Looking at the two segments, healthcare came out strong. But please bear in mind that the lab segment is more tilted toward project-related orders, hence bigger ones, resulting in higher volatility between quarters. All in all, we have a solid order backlog to convert into sales in the coming quarters. Splitting the group into healthcare and lab and looking at healthcare. Our sales came in at 249 million SEK in the quarter, an organic drop of 22%. The lab segment reported sales of $154 million for the quarter. Organic sales came in at -44%, heavily affected by the one-off type of revenue in the European clinical trial last year. Margin wise, healthcare came in at 16%. EBITA margin in the lab segment came in at 25% for the quarter. Isolated. Looking at net sales by geography for the healthcare segment, North America is the key market and will continue to be that for a long time. Having said that, South America is a very fast-growing market compared to the other markets that are slightly more mature, and our operation in that region is clearly performing according to plan. The lab segment is very well diversified when it comes to sales by geography. The largest market is now Europe, excluding Sweden. I'm now handing over to Johan Irwe to take you through the group's financial performance. Thank you, Staffan, and good afternoon all. I am pleased to be here today and take you through the numbers for the third quarter of 2024. EBITDA in the quarter amounted to 88 million SEK, which corresponds to a margin of 22%. This is lower than the same period last year and is primarily driven by a change in product mix. As Staffan just pointed out, we are. We meet challenging comparable figures from the product segments Pharmaceuticals and equipment for clinical trials, which has brought down profitability compared with last year. On a rolling 12-month basis, we are running at an EBITDA of 416 million, which equals a margin of 26%. Worth mentioning here is that the four acquisitions, which we completed during the back end of last year, are all performing in line with or above our expectations, and are all contributing to group profitability. Looking at our profitability metrics for the quarter, we have seen operating profits at similar levels to those in the third quarter of 2023. EBITDA is down 6% while net income is up 4%. The improved EBITDA in Q3 this year is explained by normalized depreciation levels in 2020. For last year, depreciation expenses were mainly driven by the high activity in our rental business for equipment for clinical trials. Net income is down from 35 million to 12 million SEK, driven by higher interest expenses on loans as well as high currency gains in the comparable quarter of 2023. Moving on to cash flow and capital efficiency. First, as a reminder, when we talk about cash flow from operations, we look at the underlying cash flow generated by our businesses, with deductions for changes in working capital as well as investments in our asset base, including leases and acquisition-related items. In the third quarter. We see a lower working capital build compared to the first half of the year. Investments include $8 million in payments related to leases and $23 million in new fixed asset investments. These fixed asset investments are mainly related to the rental business areas and production capacity increases, both of which are growth-driven. Return on capital employed, which is a KPI we have started to publish this year, was 13% for the rolling 12-month period. We have not communicated a target for this metric, but expect that we will level out around or above current levels of the high 20% plus return figures in 2023. Moving on to the balance sheet. Our financial position remains solid. Our net leverage stands at 3.3 times EBITDA. Pro forma. This is above our long-term target of being below three times EBITDA. The dollar bond issues earlier this year reduced our effective exposure and improved our maturity profile by pushing about a third of our gross debt out by almost a year to April 2027. The SEK bond matures in May of 2026. At the end of the quarter, we had more than 400 million SEK in cash and cash equivalents plus undrawn credit facilities. So from a liquidity perspective, we feel very comfortable. This was all from me. I will now hand over to Staffan again for some closing remarks.

Staffan Torstensson
12:54 - 12:55

Thank you.

Johan Irwe
12:55 - 13:56

And, so just to summarize before we open up for questions, sales growth was 26% in total, with a healthy order intake growth of 16 to 17%. Profitability remained at a healthy level, cash flow was affected by investments in growth, but cash on hand and liquidity remain strong. We monitor the net debt level cautiously when assessing new opportunities in the M&A space, and when talking about M&A, there is no stress. It has to be right. High quality coupled with a reasonable price tag, I would say. With that said, we open up for questions.

Operator
14:02 - 14:09

The next question comes from Philip Ekengren from ABG Sundal Collier. Please go ahead.

Philip Ekengren
14:12 - 14:35

Thank you. Operator. Good afternoon, Staffan and Johan. To start, I would like some color on the healthcare segment. So both generic pharma and capital goods obviously negatively impacted sales and margins here in the quarter. But can you say anything about what you've seen at the start of Q4? Anything that might have an effect on the quarter?

Johan Irwe
14:37 - 14:46

I would say that what we observed during Q3 will continue into Q4.

Staffan Torstensson
14:46 - 14:46

I would.

Johan Irwe
14:46 - 14:54

Say. I mean, the activity level is good. I would say there have been no significant changes.

Philip Ekengren
14:55 - 15:13

Okay. And you highlight in the report that you've observed some positive indicators in the US market for capital goods. Is that going to have an effect on sales, or is it more towards next year?

Johan Irwe
15:15 - 15:25

Hopefully, it will have an effect during the rest of the year. It is clear from the review that activity is picking up.

Philip Ekengren
15:26 - 15:43

Perfect. Thank you. In the lab, you seem to make investments into clinical trials equipment. Yet, it has faced some soft demand for several quarters now. Should we view this as a positive indicator of future growth, or how should we interpret that?

Staffan Torstensson
15:45 - 15:46

Definitely.

Johan Irwe
15:46 - 16:13

I guess it's a mixed picture here looking at clinical trials, us, where we have very healthy growth and growth in, adjusted for the outlier year of last year in Europe. But it's clearly us as a driver in clinical trials for organic growth.

Staffan Torstensson
16:15 - 16:15

Sure.

Philip Ekengren
16:15 - 16:50

Sounds good. And then, perhaps my final question, at least for now, you've talked previously about organic growth returning at the end of Q4. Maybe not for the quarter per se, but in the last months of Q4 at least, is that still possible or reasonable, what should we call it? Uh, and maybe also on that question, would you like to remind us of what happened last Q4, just so we know what type of comparables we're facing now?

Staffan Torstensson
16:52 - 16:53

I mean, it's clear.

Johan Irwe
16:53 - 17:34

As we have communicated earlier, the effects will fade out during Q4, but they will still be present throughout the quarter. So, I mean, we have a clean sheet when we go into next year, but of course, we also have some effects from companies bought or consolidated during Q4, which means that they will also be included in the organic calculation for the quarter.

Philip Ekengren
17:37 - 17:40

Perfect. Sounds good. That was all for me. Thanks.

Staffan Torstensson
17:40 - 17:41

Thank you.

Operator
17:45 - 17:51

The next question comes from Christian Binder from Redeye. Please go ahead.

Christian Binder
17:54 - 18:08

Hi, and thanks so much for taking my questions. Um, the first question is a follow-up on CapEx during the quarter. Should we expect that level to persist during the coming quarters, or was it more of a one-time investment, so to speak?

Johan Irwe
18:11 - 18:42

Clearly, in terms of production-related growth, there could be quarters where we invest. However, looking at investment broadly, we do not foresee it at this time, though we are hopeful for future opportunities. But when it comes to the clinical trials business.

Staffan Torstensson
18:42 - 18:42

Uh.

Johan Irwe
18:42 - 18:50

It's clear that we will continue to invest, hopefully if we see growth in that area.

Christian Binder
18:52 - 19:09

Great. Got it. And when it comes to cash conversion, can you elaborate a little bit on what has led to the soft cash conversion in recent quarters and any potential measures that you've taken to improve cash conversion going forward?

Johan Irwe
19:11 - 19:59

Thank you for the question. When it comes to cash conversion, the way we measure it, the investments we just talked about affect the cash conversion. And from the way I see it, those are kind of, I mean, growth-driven investments. So it's a positive sign. In the quarter, we saw a working capital increase, but on a much smaller basis compared to the first six months of the year. Working capital is something we constantly work on to optimize and stay on top. Um.

Staffan Torstensson
20:00 - 20:01

And clearly.

Johan Irwe
20:01 - 20:16

I mean, this is not news at all, but we're working very hard on a daily basis. I mean, both on the group level and on a company level in order to maximize cash flow.

Christian Binder
20:18 - 20:30

Great. So just one last follow-up there. So should we in the near term expect any improvements in terms of net working capital efficiency, or should we expect it to remain at the current levels?

Johan Irwe
20:33 - 20:48

I mean, I would say, you should expect to be at the same level or better. This is something we're working constantly to improve.

Christian Binder
20:49 - 20:52

All right. Perfect. That was all from my side. Thank you so much.

Staffan Torstensson
20:52 - 20:53

Thank you.

Operator
20:56 - 21:22

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Johan Irwe
21:24 - 21:38

Okay. Thank you for taking part in the earnings call, and have a nice continued day. We look forward to speaking next quarter. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…